Top Page
BriaCell Therapeutics
(TSX:BCT)
BriaCell Therapeutics (BCT) vs. iShares MSCI Canada ETF (EWC)
BriaCell Therapeutics Business Overview & Revenue Model
BriaCell Therapeutics Financial Statement Overview
| Breakdown | |||||
| TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | 0.00 | -20.49K | -19.39K | -19.44K | -18.74K | EBIT |
| -27.32M | ― | -23.27M | -15.29M | -6.97M | -3.94M | EBITDA |
| -30.67M | ― | -22.37M | -34.05M | -6.95M | -3.96M | Net Income Common Stockholders |
| -11.59M | ― | -20.30M | -11.58M | -2.90M | 1.39M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 5.01M | 862.09K | 21.25M | 41.04M | 57.27M | 19.46K | Total Assets |
| 9.36M | 5.87M | 27.16M | 42.58M | 58.04M | 478.31K | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 25.99K | 228.75K | Net Debt |
| -5.01M | -862.09K | -21.25M | -41.04M | -57.24M | 209.29K | Total Liabilities |
| 6.14M | 8.56M | 30.94M | 32.25M | 782.24K | 3.77M | Stockholders Equity |
| 3.60M | -2.38M | -3.78M | 10.33M | 57.26M | ― |
| Cash Flow | Free Cash Flow | ||||
| -21.99M | -24.58M | -23.74M | -12.48M | -7.75M | ― | Operating Cash Flow |
| -21.99M | -24.13M | -23.74M | -12.48M | -7.75M | ― | Investing Cash Flow |
| -831.80K | -681.80K | 0.00 | 0.00 | 0.00 | ― | Financing Cash Flow |
| 21.60M | 4.42M | 3.95M | -3.74M | 65.00M | 1.08M |
BriaCell Therapeutics Technical Analysis
BriaCell Therapeutics Risk Analysis
BriaCell Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.38B | 3.31 | -45.11% | 3.29% | 16.82% | 0.04% | |
44 Neutral | $19.03M | ― | -76.00% | ― | ― | 66.13% | |
43 Neutral | C$27.66M | ― | -478.64% | ― | ― | 56.78% | |
36 Underperform | C$28.26M | ― | 136.37% | ― | 53.98% | -37.86% | |
30 Underperform | C$43.23M | ― | 281.56% | ― | ― | 71.24% |
BriaCell Therapeutics Corporate Events
BriaCell Therapeutics has announced promising Phase 3 clinical data for its lead product, Bria-IMT™, in treating metastatic breast cancer. The study highlights the potential of specific biomarkers to predict patient responses, which could enhance treatment outcomes and extend patient survival. The findings suggest that positive delayed-type hypersensitivity and favorable neutrophil-to-lymphocyte ratios are linked to longer progression-free survival. The treatment was well-tolerated, indicating a favorable safety profile, and the results could lead to full approval and marketing authorization for Bria-IMT in the future.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Underperform.
BriaCell Therapeutics faces major financial challenges with no revenue and consistent losses, posing significant risks to its financial stability. While technical indicators show some positive momentum, valuation concerns persist. Recent corporate developments in cancer treatment and successful financing offer potential upside but are not sufficient to offset the overall weak financial health.
To see Spark’s full report on TSE:BCT stock, click here.
BriaCell Therapeutics has successfully closed a public offering, raising approximately $13.8 million through the sale of 3,066,666 units. The proceeds from this offering will be used for working capital, general corporate purposes, and advancing business objectives, potentially strengthening the company’s position in the biotechnology industry.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics’ stock score is primarily impacted by its weak financial health, marked by no revenue and consistent losses. While technical analysis shows some positive momentum, valuation concerns persist with a negative P/E ratio. Notably, recent corporate developments in cancer treatment offer potential upside, balancing some of the financial and valuation challenges.
To see Spark’s full report on TSE:BCT stock, click here.
BriaCell Therapeutics presented promising data at the AACR 2025, showcasing their lead product candidate, Bria-IMT™, which demonstrated benchmark-beating survival and clinical benefits in heavily pretreated metastatic breast cancer patients. The company’s new Bria-OTS+ platform also showed significant potential in activating the immune system, with plans to advance into clinical studies for breast and prostate cancer, potentially enhancing BriaCell’s positioning in the oncology market.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics’ stock score is primarily impacted by its weak financial health, marked by no revenue and consistent losses. While technical analysis shows some positive momentum, valuation concerns persist with a negative P/E ratio. Notably, recent corporate developments in cancer treatment offer potential upside, balancing some of the financial and valuation challenges.
To see Spark’s full report on TSE:BCT stock, click here.
BriaCell Therapeutics has announced the pricing of a $13.8 million public offering, selling 3,066,666 units at $4.50 each. The proceeds will be used for working capital, general corporate purposes, and advancing business objectives. The offering is expected to close on April 28, 2025, and the warrants included in the units will commence trading on Nasdaq under the symbol ‘BCTXZ’.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Underperform.
BriaCell Therapeutics’ overall score is primarily weighed down by its financial instability, characterized by no revenue and consistent losses. While the technical analysis provides some neutral insights, the valuation concerns due to lack of profitability and dividend yield further impact the score. However, promising corporate developments in cancer treatment provide a potential upside, although significant financial risks persist.
To see Spark’s full report on TSE:BCT stock, click here.
BriaCell Therapeutics has announced a significant milestone in its ongoing Phase 1/2a study of Bria-OTS, a personalized off-the-shelf immunotherapy for metastatic breast cancer. The company reported a complete resolution of lung metastasis in a patient with hormone receptor-positive breast cancer, demonstrating the potential efficacy of Bria-OTS as a monotherapy. This development highlights BriaCell’s innovative approach in cancer treatment and may enhance its positioning in the biotechnology sector, offering new hope for patients with limited treatment options.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Underperform.
BriaCell Therapeutics faces substantial financial challenges with no revenue and ongoing losses, reflected in a low financial performance score. Despite advances in cancer research and strategic efforts in immunotherapy, the company’s overall financial instability and valuation concerns weigh heavily on its stock score.
To see Spark’s full report on TSE:BCT stock, click here.
BriaCell Therapeutics announced it will present four clinical data presentations at the 2025 American Society of Clinical Oncology Annual Meeting. These presentations, which include updates on trials involving Bria-IMT and Bria-OTS in metastatic breast cancer, highlight the company’s ongoing efforts to advance cancer treatment options. The impact of these presentations could enhance BriaCell’s positioning in the biotechnology industry and provide valuable insights for stakeholders interested in cancer immunotherapy advancements.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Underperform.
BriaCell Therapeutics faces significant financial challenges with no revenue and ongoing operational losses, leading to a low overall score. Despite promising corporate developments in cancer treatment, the lack of profitability and reliance on external financing weigh heavily on its financial health and stock performance.
To see Spark’s full report on TSE:BCT stock, click here.
BriaCell Therapeutics has announced significant progress in its pivotal Phase 3 clinical study of Bria-IMT combined with an immune checkpoint inhibitor for treating advanced metastatic breast cancer. With over 75 patients enrolled across 54 clinical sites in the United States, the company is on track to complete patient enrollment by late 2025 or early 2026, with potential top-line data available in the first half of 2026. The study’s success could lead to full approval and marketing authorization for Bria-IMT, offering new hope for patients with unmet medical needs.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Underperform.
BriaCell Therapeutics faces significant financial challenges with no revenue and ongoing operational losses, leading to a low overall score. Despite promising corporate developments in cancer treatment, the lack of profitability and reliance on external financing weigh heavily on its financial health and stock performance.
To see Spark’s full report on TSE:BCT stock, click here.
BriaCell Therapeutics has announced positive survival data from its Phase 2 study of Bria-IMT plus checkpoint inhibitors, showing a median overall survival of 17.3 months in hormone receptor positive metastatic breast cancer patients, surpassing the 14.4 months associated with the current standard, TRODELVY. This development suggests a promising therapeutic option for HR+ and triple-negative breast cancer patients, potentially addressing unmet medical needs and offering a well-tolerated treatment alternative.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Underperform.
BriaCell Therapeutics’ overall score reflects a challenging financial position with no revenue and consistent losses, posing significant risks. The bearish technical indicators add to the negative outlook. However, promising corporate developments in cancer treatment and strategic financing efforts provide some potential upside.
To see Spark’s full report on TSE:BCT stock, click here.
BriaCell’s subsidiary, BriaPro, is advancing the development of novel antibodies targeting the B7-H3 antigen, a promising target in cancer treatment due to its high expression on tumor and immune cells. These antibodies are expected to be integrated into BriaPro’s proprietary Bria-TILsRx™ platform, which aims to enhance T cell activity against tumors, potentially offering significant therapeutic benefits across multiple cancer types. The company has filed for US patents and plans to seek international patent protection, positioning itself as a key player in the immuno-oncology space.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics’ overall score reflects the company’s challenging financial position, with no revenue generation and consistent operational losses, posing significant financial risks. Technical analysis suggests a bearish trend, while valuation highlights concerns about profitability. However, recent corporate events are promising, with advancements in immunotherapy and successful financing efforts providing some upside potential.
To see Spark’s full report on TSE:BCT stock, click here.
BriaCell Therapeutics announced it will present clinical and preclinical data through three posters at the 2025 American Association for Cancer Research Annual Meeting. This presentation highlights BriaCell’s ongoing efforts in cancer immunotherapy, potentially enhancing its industry positioning and offering significant insights for stakeholders regarding its innovative treatments.
BriaCell Therapeutics has received a positive recommendation from the Data Safety Monitoring Board to continue its pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor for metastatic breast cancer, with no safety concerns identified. This development underlines the potential of BriaCell’s novel immunotherapy to significantly impact cancer treatment, particularly in improving survival and quality of life for patients with metastatic breast cancer.
BriaCell Therapeutics Corp. announced the successful outcomes of its annual general shareholder meeting, where 36.26% of its common shares were voted. Shareholders approved all proposed resolutions, including the re-appointment of MNP LLP as auditors and the election of directors with high approval ratings, indicating strong shareholder support for the company’s leadership and strategic direction.
BriaCell Therapeutics has successfully closed its public offering, raising $3.05 million in gross proceeds through the sale of 762,500 common shares. The company plans to use the funds for working capital, general corporate purposes, and advancing its business objectives, marking an essential step in strengthening its financial position in the biotechnology sector.